A retrospective chart review was conducted over a 5-year period (1988 Over the last decade, it has been our clinical experience that, despite a documented decrease in the sputum bacillary count during the initial treatment, some patients' conditions failed to improve symptomatically and they continued to have toxic reactions, exhibiting high fever, progressive weight loss, anorexia, and an inability to thrive. The contrast between the favorable sputum response and the overall toxic picture suggests that the fever and its attendant consequences may be due to the release of tubercle protein from a large amount of destroyed tubercle bacilli. We found that, under these circumstances, a course of corticosteroid therapy may be beneficial and, most importantly, safe. To further confirm our clinical observation, we conducted a 5-year retrospective chart review for all of the patients with TB admitted to our hospital with the purpose of assessing the role of prednisone as adjunctive therapy in the management of pulmonary TB.
METHODS
The Pulmonary Medicine Division's office files of all the patients with TB who were admitted between January 1, 1989 , and December 31, 1993, to our 900-bed inner-city teaching hospital were reviewed (n= 1, 809 The follow-up sputum smears were defined as significantly decreased if the bacillary count dropped by two grades; for example, from >9 per field to I to 9 per 10 fields or from 1 to 9 per field to 1 to 9 per 100 fields.
To rule out other causes of fever, serial blood cultures, sputum, and urine cultures, and, when appropriate, a total body gallium -67 scintigraphy seeking occult abscesses were performed. Treatment with antituberculosis drugs was withheld for up to 48 h and temperature response was monitored. A screening for occult malignant disease was also performed. A trial of intravenous broadspectrum antibiotic therapy was administered for 3 to 4 days. In patients with positive HIV serologic test results, careful evaluation was performed to rule out other opportunistic infections. After TB itself was deemed to be the probable cause of continued fever spikes, the patients were given 40 mg of oral prednisone as a single daily dose along with the antituberculosis drugs. If there was no response, the dose was increased to 30 mg twice a day. As there was no clinical suspicion of adrenal insufficiency in this group of patients, we did not measure the baseline serum cortisol level.
After the addition of prednisone, temperature response (every 4 h), signs, and/or symptoms of systemic toxic reactions (general responsiveness, appetite, night sweats, low blood pressure, tachycardia), weekly weight, and nutritional status (using serum albumin as the marker) were monitored. The major concern of adding steroid therapy was possible dissemination of TB. This potential complication was monitored by close attention to a patient's general status, sputum bacillary count, and chest radiograph. Other potential side effects of steroid therapy such as diabetes, opportunistic infections, adrenal suppression, etc, were also closely monitored. In those patients with history of TB, the last drug susceptibility result available and the patient's history of compliance to therapy were used in selecting the current chemotherapy regimen. When new drugs were believed to be indicated for these patients, a minimum of two drugs were added at a time. For all patients with newly diagnosed conditions, chemotherapy consisting of a minimum of four drugs was started pending the availability of susceptibility reports. In most patients with newly diagnosed conditions, drug susceptibility studies were available only after the initiation of corticosteroid therapy; therefore, they were only used to confirm the impression indicated by the rapid decrease in bacillary count. Guidelines used to taper off and cease the prednisone dose were as follows: (1) lack of fever with temperature exceeding 37.2°C for 48 h, (2) evidence of weight gain of more than 1.8 kg; or (3) improvement in appetite and general well-being. Patients were discharged from the hospital and followed up in our pulmonary clinic after their sputum smears were negative for tubercle bacilli; their medical and socioeconomic problems also were addressed.
Statistical Analysis
Our data were collected in paired fashion with each patient serving as his/her own control. Nonparametric methods were applied for statistical analysis because of the small sample size (n=12). The Wilcoxon matched-pairs signed-ranks test was performed to test the paired differences between before-and-after steroid drug administration (temperature differences, albumin level, and weight changes). Friedman two-way analysis of variance (ANOVA) was used to compare the three related data (patient's weight at hospital admission, before using steroids, and at hospital discharge). Table 1 lists the characteristics and clinical profiles of the study subjects. Eleven men and one woman were studied. Their ages ranged from 20 to 54 years (mean ±SD=38.4± 10.9 years, median=38 years). Eleven patients suffered from far-advanced cavitary pulmonary TB and their sputum smears/cultures were positive for Mycobacterium tuberculosis; one patient had miliary TB (bronchoscopic washing smear/culture confirmed). Six patients were alcohol abusers and three patients admitted to intravenous drug use. Seven patients underwent HIV serologic tests; one had a positive test. The susceptibility studies of TB organisms isolated in all 12 patients showed no resistance to commonly tested antituberculous drugs (INH, RIF, SM, and EMB).
RESULTS
Five patients had a history of TB and were noncompliant during their prior therapy, three of them had at least one prior cycle of therapy for TB, one had two cycles of therapy, and one had seven prior hospital admissions for TB within 1 year. The prior chemotherapy regimen, the drug therapy started at the time of hospital admission, and the subsequent modification of chemotherapy regimen are shown in Table 2 .
The initial sputum bacillary count for each of the 11 patients with cavitary pulmonary TB was 3+ organisms; the bronchial washing bacillary count of the patient with miliary TB was 1+ organism. The antituberculosis therapy regimen consisted of a four-or five-drug combination as listed in Table 1 ; therapy was initiated on the day of hospital admission in seven patients, on the second day in four patients, and on the fifth day in one patient. After 16 to 38 days (mean ± SD=27.56 ± 8 days) of therapy, the bacillary count had decreased by two points in the 11 patients with cavitary pulmonary TB. Despite the decrease in sputum bacillary count, all patients continued to have spike temperature ranging from 38.3°C to 40.5°C (mean ± SD=39.6°C ± 0.6°C, median=39.6°C), which did not respond to conventional antipyretics. All patients received nutritional support by enteral or parenteral hyperalimentation. Nine patients continued to lose weight. The mean (± SD) hospital admission weight for all of the 12 patients was 55.4±5.1 kg (median=54.5 kg), which dropped to a mean (± SD) of 53.6 ± 5.7 kg (median=53.5 kg) the day prior to administration of prednisone. The administration of prednisone was initiated from 18 to 53 days (mean±SD=33.9±9.8 days, median=34 days) after admission to the hospital. In three out of the five retreatment patients and in one of the seven patients with newly diagnosed conditions, drug susceptibility reports were available prior to the addition of prednisone. In the absence of drug susceptibility results, a decrease in sputum bacillary count by two grades on three consecutive sputum samples was used to indicate that the organisms were susceptible to the drug regimen of that patient. The fever declined dramatically after prednisone was added to the drug regimen (Fig 1) , with a mean temperature decreasing within 24 h of the initiation of prednisone therapy from a spike mean (±SD) of 39.60C±0.60C to 38.10C±0.60C (Z=3.0594, p=0.0022). The temperature continued to decrease but less impressively in the form of low-grade fever and finally normalized at the time the corticosteroid therapy was discontinued. The total mean (±SD) duration of steroid therapy was 20.1 ± 9 days (range, 4 to 35 days, median=20.5 days).
All of the study subjects had gained weight, ranging from 0.9 to 11.25 kg (mean±SD=4.5±3.24 kg, median=3.825 kg). The average weight of all the study subjects before the addition of prednisone was 53.6±5.67 kg (SD) (median=53.5 kg), which had increased to 58.1 ± 6.435 kg (SD) (median=57.8 kg) at the time of hospital discharge. Figure 2 shows the weight changes from the day of hospital admission, to the day before steroid drugs were administered, to the day of hospital discharge. Friedman two-way ANOVA test was statistically significantly different for these three related data (X2 =13.04, p=0.0015). A patient's weight had significantly increased on the day of hospital discharge compared with his/her weight the day before administration of prednisone (Z=3.0594, p=0.0022). However, no difference was noted between a patient's weight at hospital admission and the day before administration of prednisone (Z=1.5559, p=0.1197).
The serum albumin level increased significantly, from an average of 2.51 ± 0.4 (SD) g/dL to 3.21 ± 0.4 (SD) g/dL. Figure 3 displays attributable to prednisone for any of the 12 study subjects. The average duration of therapy with the addition of prednisone was 20.1 ± 9 (SD) days (median=20.5 days). The total length of hospital stay was 49.3±15 (mean±SD) days, which is substantially paradoxically longer than the average hospital stay.
DISCUSSION
This study demonstrates that a selected group of patients with advanced or far-advanced cavitary pulmonary TB showed bacteriologic improvement with modern chemotherapy, yet their conditions failed to improve clinically and they continued to have high fever spikes, continued to have toxic reactions, lost weight, and failed to thrive. They all benefited from the addition of prednisone to their drug regimens, and within 24 h, a significant drop in fever resulted. Within 3 weeks, the patients had gained a significant amount of body weight, their serum albumin levels had improved, and the systemic toxic reactions were resolved. Most of the patients responded to a single 40- The most recent clinical trial was a study of shortcourse chemotherapy in India23 (1983) in which prednisone was given in the initial 8 weeks along with INH, rifampicin, SM, and PZA. Prednisone did not influence the speed of sputum conversion, the response to chemotherapy, the rate of disappearance of cavities, or the rate of bacteriologic relapse in patients with drug-susceptible organisms or in patients showing resistance to a single drug. Among patients with strains resistant to more than one drug, the group receiving prednisone had an unfavorable response. The authors concluded that there was no role for steroids in short-course antituberculosis chemotherapy. It must be noted, however, that the daily dose of prednisone used in this study was only 20 mg (Table 3) .
A favorable report was mentioned in a 1988 case report of an HIV-infected patient with disseminated TB accompanied by hectic fever and weight loss despite effective quadruple chemotherapy; there was response to the addition of corticosteroids.24 A 1991 editorial on corticosteroids and TB recommended the addition of corticosteroids to antituberculosis treatment in the management of systemic symptoms and in moribund patients.25 A 1993 review article summarized the role of corticosteroids in the management of pleuropulmonary disease as "appropriate in patients with severe systemic toxicity, persistent pleuritic pain, or slow resolution of effusions. "7 In pleural disease, corticosteroids decrease the systemic and local symptoms related to tuberculoprotein, limit the organization of pleural exudates and subsequent fibrosis, and reduce the chest wall deformity and patients with TB with high-grade fever and cachexia generated more TNF than the PBMC from the control subjects. In patients being treated for septic shock, endotoxin release can be related to the administration of antibiotics, and the rate of endotoxin release varies with the antibiotic used.6 Thus, a similar mechanism could explain the high fever, weight loss, and toxic reactions seen in our patients who received tuberculocidal drugs. Further studies with serial measurement of TNF, PGE2, and other mediators of inflammation in our patient population might help to clarify this better. The therapeutic benefit of glucocorticoids appears to derive chiefly from their suppression of immunologic and inflammatory responses. Corticosteroids are used as antipyretic agents in bacterial infections in conjunction with antibiotics26 to manage the hypersensitivity reactions that occur with antituberculosis drugs.35'36 They also decrease the release of TNF by alveolar macrophages.37 Pentoxifylline and thalidomide are the two other drugs known to inhibit TNF-a production. Thalidomide inhibits TNF-a production by enhancing the degradation of TNF-a mRNA; it is the drug of choice for the treatment of erythema nodosum leprosum (ENL), an acute inflammatory complication occurring in 30% of patients with lepromatous leprosy, usually associated with the initiation of multidrug therapy. The fever, anorexia, and arthralgia associated with ENL respond promptly to the addition of thalidomide. Selective inhibition of TNF-a by thalidomide without reduction of humoral or cellular immunity of patients makes this the drug of choice in the management of ENL.38 Such a drug, which would promptly reduce the toxic symptoms seen among our patient group but without inhibition of the patient's cellular or humoral immunity, would be better than prednisone. This is especially true in patients with AIDS with TB in whom the intact cellular immune system is crucial. We are not aware of any clinical trials on the use of thalidomide or pentoxifylline for the management of inflammatory toxic reactions in patients with TB. Further studies are required.
Decreasing the systemic toxic reactions of our patients with prednisone improved the appetite and promoted weight gain, while the appetite stimulants and anabolic steroids would be safer than prednisone to use in patients with TB; their benefit in our study group patients is unknown. In most patients, daily administration of prednisone is sufficient; twice daily corticosteroids may suppress a fever more effectively because prednisone has a short plasma half-life of 2 to 3.5 h.39,40 Furthermore, rifampicin can decrease the half-life of prednisone by its effect on liver enzyme induction.41 Doubling the dose of prednisone is recommended in patients receiving rifampicin and prednisone simultaneously.42 Three of our patients did not respond to once-a-day prednisone but showed a response to a twice-daily dose. The approximate duration of the need for prednisone appears to be 4 to 6 weeks depending on the system involved. 8 The total in-hospital days for our patient group was substantially longer than is normal for patients with TB generally, primarily due to the various diagnostic workup required to rule out other causes of fever and weight loss, and also due to the nature of their far-advanced cavitary pulmonary TB. With the availability of faster drug susceptibility studies using a specific radiometric method (Bactec, Becton-Dickinson Diagnostic Instrument Systems, Sparks, MD), we will be able to initiate the addition of corticosteroids much earlier in the course of therapy, which will benefit the patients and decrease hospital stays. CONCLUSION We identified a subset of patients with advanced pulmonary TB who had persistently high fever and progressive weight loss even though their sputum bacillary count decreased rapidly with effective tuberculocidal drugs. Both fever and nutritional status responded favorably to the addition of prednisone along with the antituberculosis regimen. Patients who did not respond to once-daily prednisone responded well to twice-daily. No adverse effects related to prednisone were observed.
We are gratified by the results of this study, but recognize the limitations associated with our retrospective study of only 12 cases; there is need for randomized controlled clinical trials. Also, the patient population we studied came from a homogeneous, low socioeconomic urban minority group, one with the highest incidence of TB in our society. 
